Pharmacometrics refers to the analysis of experiments and clinical studies, in particular pharmacokinetic and pharmacodynamic studies (PKPD) for the purposes of quantitation of drug clearance in the body, drug effects and side effects, disease progression, the optimisation of study designs, and Pharmacometric research focuses on nonlinear mixed effects (”population”) models.

Such models describe data, generally is the response-time profiles observed in a clinical trial, by a basic model, accounting for the general structure of the underlying system, and a set of hierarchical variability components, accounting for variability between subjects, within subjects over time and remaining between observation variability.

Research at the Pharmacometrics group can be divided into two main categories:

  • the analyses of dose-concentration-response data from trials and clinical therapeutic drug monitoring data to understand therapies with existing drugs with the aim of allowing improved therapy and individualized therapy and
  • the utilization of the developed models for the purpose of designing future prospective studies, deciding upon dosing strategies and other developmental decisions.

We mainly try to employ the Population Pharmacometrics approach to answer questions arising from the clinical setting and work closely together with several clinical teams in Brisbane and worldwide.

View more about ethics applications here. 

Areas of research within Pharmacometrics include:

  • Optimising drug therapy for:
    • antibiotics
    • infectious diseases, including critical care, cystic fibrosis, malaria, sepsis, tuberculosis/HIV, solid organ transplantation, immunosuppressant agents
    • effects of body composition on pharmacokinetics, for obese, paediatric and oncology patients
    • pharmacogenomic subgroups

Some of the software used in within this research area includes:

  • NONMEM
  • PsN, WFN
  • Xpose, R,
  • PopED, WinPOPT
  • Monolix
  • Berkley Madonna